Eisai R&d Management Co., Ltd.

Anand Selvaraj

John JianShi Wang

Ming-Hong Hao

Dominic J Reynolds

Sudeep Prajapati

Takashi Satoh

Peter G Smith

Arani Chanda

Kristen Sanders

George Moniz

Kenshi Yoshida

Peter Smith

Dominic Reynolds

Sundeep Prajapati

Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.

Combination therapies for the treatment of hepatocellular carcinoma

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

Crystalline FGFR4 inhibitor compound and uses thereof

Provided herein is a combination of agents for reducing cell viability and/or cell proliferation. The combination comprises an FGFR4 inhibitor and an EGFR inhibitor.

Drug combinations for reducing cell viability and/or cell proliferation

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Pyrimidine FGFR4 inhibitors

Growing community of inventors

Cambridge, MA, United States of America

Anand Selvaraj